^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SER-401

    i
    Other names: SER-401
    Associations

    News

    Trials
    Company:
    Seres Therap
    Drug class:
    Immunomodulator, Bacteria replacement
    Related drugs:
    Associations

    News

    Trials
    6ms
    MCGRAW: Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (clinicaltrials.gov)
    P1, N=14, Completed, Parker Institute for Cancer Immunotherapy | Phase classification: P1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • SER-401
    over3years
    Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (clinicaltrials.gov)
    P1b, N=14, Active, not recruiting, Parker Institute for Cancer Immunotherapy | Trial primary completion date: Feb 2021 --> Jan 2022 | Trial completion date: Feb 2022 --> Jan 2023
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    BRAF (B-raf proto-oncogene)
    |
    Opdivo (nivolumab) • SER-401
    almost4years
    Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (clinicaltrials.gov)
    P1b, N=14, Active, not recruiting, Parker Institute for Cancer Immunotherapy | Recruiting --> Active, not recruiting | N=30 --> 14
    Clinical • Enrollment closed • Enrollment change • Combination therapy
    |
    BRAF (B-raf proto-oncogene)
    |
    Opdivo (nivolumab) • SER-401